SciCombinator

Discover the most talked about and latest scientific content & concepts.

J de Bono, RK Ramanathan, L Mina, R Chugh, J Glaspy, S Rafii, S Kaye, J Sachdev, J Heymach, DC Smith, JW Henshaw, A Herriott, M Patterson, NJ Curtin, LA Byers and ZA Wainberg
Abstract
Talazoparib inhibits poly(ADP-ribose) polymerase (PARP) catalytic activity, trapping PARP1 on damaged DNA and causing cell death in BRCA1/2-mutated cells. We evaluated talazoparib therapy in this 2-part, phase I, first-in-human trial. Antitumor activity, maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of once-daily talazoparib were determined in an open-label, multicenter, dose-escalation study (NCT01286987). The MTD was 1.0 mg/day, with an elimination half-life of 50 hours. Treatment-related adverse events included fatigue (26/71 patients; 37%) and anemia (25/71 patients; 35%). Grade 3 to 4 adverse events included anemia (17/71 patients; 24%) and thrombocytopenia (13/71 patients; 18%). Sustained PARP inhibition was observed at doses ≥0.60 mg/day. At 1.0 mg/day, confirmed responses were observed in 7/14 (50%) and 5/12 (42%) patients with BRCA mutation-associated breast and ovarian cancers, respectively, and in patients with pancreatic and small cell lung cancer. Talazoparib demonstrated single-agent antitumor activity and was well tolerated in patients at the recommended dose of 1.0 mg/day.
Tweets*
15
Facebook likes*
0
Reddit*
0
News coverage*
37
Blogs*
1
SC clicks
0
Concepts
Breast cancer, Small cell carcinoma, Leukemia, DNA repair, Metastasis, DNA, Lung cancer, Cancer
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com